我武生物(300357) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was CNY 228,471,779.62, representing a 5.65% increase compared to CNY 216,249,528.11 in the same period last year[5]. - Net profit attributable to shareholders decreased by 3.71% to CNY 74,342,067.14 from CNY 77,207,320.73 year-on-year[5]. - Total operating revenue for the current period reached ¥228,471,779.62, an increase of 5.2% compared to ¥216,249,528.11 in the previous period[17]. - Net profit for the current period was ¥71,551,023.50, a decrease of 3.2% from ¥73,915,884.55 in the previous period[18]. - Earnings per share (EPS) for the current period was ¥0.1420, down from ¥0.1475 in the previous period[19]. Cash Flow - The net cash flow from operating activities increased significantly by 96.21%, reaching CNY 85,883,668.65 compared to CNY 43,771,270.48 in the previous year[5]. - The company's cash flow from operating activities showed a positive trend, contributing to overall financial stability[19]. - Cash inflow from investment activities totaled ¥351,992,400.12, significantly higher than ¥33,318,994.00 in the prior period, marking an increase of over 950%[21]. - The net cash flow from financing activities was negative at -¥61,466,355.72, compared to a positive net flow of ¥666,141.03 in the previous period[21]. - The total cash and cash equivalents at the end of the period amounted to ¥134,863,657.04, down from ¥596,910,301.38 at the end of the previous period[21]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,675,508,295.28, a decrease of 1.24% from CNY 2,709,124,934.20 at the end of the previous year[5]. - Total liabilities decreased to ¥145,128,594.44 from ¥250,295,258.85, indicating a significant reduction[16]. - Total current assets decreased to CNY 1.61 billion from CNY 1.65 billion, a decline of about 2.0%[14]. - The company's trading financial assets decreased to CNY 140.66 million from CNY 196.09 million, a decline of about 28.4%[14]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 35,844, with the largest shareholder holding 38.86% of the shares[10]. - The company’s major shareholder, Zhejiang Wawu Management Consulting Co., Ltd., holds 203.45 million shares, representing a significant ownership stake[12]. Product Performance - Sales revenue from the Dust Mite Drops product was CNY 215,804,998.41, up 4.10% year-on-year, while the sales of Artemisia Pollen Sublingual Drops surged by 43.52% to CNY 9,300,884.66[8]. Research and Development - The company has initiated clinical trials for its "Dust Mite Membrane Agent," with the first subject enrolled in the I phase clinical trial[13]. - The company received a formal acceptance notice for its "Dermatitis Diagnostic Patch 02" drug clinical trial application from the National Medical Products Administration in March 2025[13]. Other Financial Metrics - The weighted average return on equity decreased to 3.11% from 3.47% year-on-year[5]. - The basic earnings per share decreased by 3.73% to CNY 0.1420 from CNY 0.1475 in the same period last year[5]. - Research and development expenses were ¥29,641,964.59, slightly down from ¥30,563,652.07, indicating a focus on cost management[17]. - The company reported an investment income of ¥151,575.33, recovering from a loss of ¥363,771.21 in the previous period[18].